Copenhagen 2016 Registration Programme Exhibitor Information Virtual Exhibition Satellite Meetings Glaucoma Day 2016 Hotel Star Alliance

10 - 14 Sept. 2016, Bella Center, Copenhagen, Denmark

This Meeting has been awarded 27 CME credits


escrs app advert yo advert


Search Title by author or title

Implantation of Scharioth macular lens in patients with age-related macular degeneration: results of a prospective European multicenter clinical trial

Poster Details

First Author: S. Srinivasan UNITED KINGDOM

Co Author(s):    G. Scharioth   A. Riehl   I. Tanev   P. Rozsival   F. Balta   E. van Acker     

Abstract Details


To report the three months visual outcomes following implantation of the Scharioth add- on injectable macular lens (SML) in previously pseudophakic eyes with age related macular degeneration (AMD).


Prospective European mutlicenter clinical trial. Study centers included Ayr, Scotland, Recklinghausen, Germany, Kiel, Germany, Sofia, Bulgaria, Hradec Kralove, Czech Republic, Bucharest, Romania, Brussels, Belgium.


31 pseudophakic patients with dry or inactive wet AMD that satisfied the inclusion criteria were recruited. The inclusion criteria were: age over 55 years, corrected distance visual acuity (CDVA) of 0.1 to 0.4 (decimal), improvement of at least three lines of corrected near visual acuity (CNVA) when tested with a +6.0 D reading addition at 15 cms, compared to a +2.5 D reading addition at 40 cms with a ETDRS near vision chart. Only eye of each patient was implanted with the SML. Patients were examined at 1 day, 1 week, 1 and 3 months post operatively.


There were no intraoperative complications. 2 patients had SML explanted due to postoperative glare /halos. The mean CDVA remained unchanged 0.18 decimal preoperatively compared to at 3 months postoperative visit. The CNVA improved 0.25 preoperatively to 0.55 decimal at 3 months time gate.


The injectable add- on SML appears to be safe and effective in the short to medium term in improving the CNVA in patients with AMD. Data suggests that the CDVA remains unaffected following the implantation of SML. Testing of CNVA at 15 cms with a +6.0 D near addition seems to be effective screening tool in patient selection. Further data is needed to assess the long-term safety and efficacy of this implant.

Financial Disclosure:

One or more of the authors gains financially from product or procedure presented

Back to Poster listing